Supportive care including growth factors in myelodysplastic syndromes

Reviews in Clinical and Experimental Hematology

Volumn 8, Issue 2, 2004, Pages

  Gardin, Claude ^a,b   Fenaux, Pierre ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ASCORBIC ACID; DANAZOL; DEFEROXAMINE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERLEUKIN 11; RECOMBINANT ERYTHROPOIETIN; THROMBOPOIETIN; GROWTH PROMOTOR;

ACUTE GRANULOCYTIC LEUKEMIA; AGRANULOCYTOSIS; ALLOIMMUNIZATION; ANEMIA; ARTHROPATHY; BLOOD TRANSFUSION; CHELATION THERAPY; DIGESTIVE SYSTEM FUNCTION DISORDER; ERYTHROCYTE; HEALTH CARE; HUMAN; IRON CHELATION; LIFE EXPECTANCY; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; QUALITY OF LIFE; RASH; REVIEW; RISK FACTOR; THROMBOCYTOPOIESIS; ZINC DEFICIENCY; BLEEDING; ERYTHROCYTE TRANSFUSION; THROMBOCYTOPENIA;

ANEMIA; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN, RECOMBINANT; GROWTH SUBSTANCES; HEMORRHAGE; HUMANS; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; THROMBOCYTOPENIA;

EID: 22044458308     PISSN: 11270020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Greenberg P, Cox C, LeBeau M, et al. International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes. Blood 89: 2079-2088, 1997
2. Jansen AJ, Essink-Bot ML, Beckers, et al. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol 121: 270-274, 2003
3. Sanz, G.F, Sanz, MA, Vallespí T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 74: 395-408, 1989
4. Beutler E, Hoffbrand AV, Cook JD. Iron deficiency and overload. Hematology (Am Soc Hematol Educ Program): 40-61, 2003
5. Sashida G, Takaku TI, Shoji N, et al. Clinico-hematologic features of myelodysplastic syndrome presenting as isolated thrombocytopenia: an entity with a relatively favorable prognosis Leuk Lymphoma 44: 653-658, 2003
6. Bick RL. Acquired platelet function defects. Hematol Oncol Clin North Am 6: 1203-1228, 1992
7. Mittelman M, Zeidman A. Platelet function in the myelodysplastic syndromes. Int J Hematol 71: 95-98, 2000
8. Manoharan A, Brighton T, Gemmell R, et al. Platelet dysfunction in myelodysplastic syndromes: a clinicopathological study Int J Hematol 76: 272-278, 2002
9. Zeidman A, Sokolover N, Fradin Z, et al. Platelet function and its clinical significance in the myelodysplastic syndromes. Hematol J 5: 234-238, 2004
10. Hebbar M, Kaplan C, Caulier MT, et al. Low incidence of specific anti-platelet antibodies detected by the MAIPA assay in the serum of thrombocytopenic MDS patients and lack of correlation between platelet autoantibodies, platelet lifespan and response to danazol therapy. Br J Haematol 94: 112-115, 1996
11. Ewout J Houwerzijl, Nel R Blom et al. Increased peripheral platelet destruction and caspase-3-independent programmed cell death of bone marrow megakaryoctes in myelodysplastic patients Blood, 10.1182/Blood-2004-06-2108 (Epub ahead of print)
12. Pomeroy C, Oken MM, Rydell RE, et al. Infection in the myelodysplastic syndromes. Am J Med 90: 338-344, 1991
13. Oguma S, Yoshida Y, Uchino H et al. Infection in myelodysplastic syndromes before evolution into acute non-lymphoblastic leukemia. Int J Hematol 60: 129-36, 1994
14. Martin S, Baldock SC, Ghoneim AT et al. Defective neutrophil function and microbicidal mechanisms in the myelodysplastic disorders. J Clin Pathol 36: 1120-1128, 1983
15. Ito Y, Kawanishi Y, Shoji N, et al. Decline in antibiotic enzyme activity of neutrophils is a prognostic factor for infections in patients with myelodysplastic syndrome. Clin Infect Dis 31: 1292-1295, 2000
16. Shikama Y, Shichishima T, Ohto H et al. Neutrophil-specific reduction in the expression of granulocyte - macrophage colony-stimulating factor receptor subunits in myelodysplastic syndromes. Br J Haematol 111: 863-872, 2000
17. Fuhler GM, Knol GJ, Drayer AL, et al. Impaired interleukin-8- and GRO-induced phosphorylation of extracellular signal-regulated kinase result in decreased migration of neutrophils from patients with myelodysplasia. J Leukoc Biol 23: 2004 (Epub ahead of print)
18. Tsukada H, Chou T, Ishizuka Y et al. Disseminated Mycobacterium avium-intracellulare infection in a patient with myelodysplastic syndrome (refractory anemia). Am J Hematol 45: 325-329, 1994
19. Gupta P, LeRoy SC, Luikart SD, et al. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leuk Res 10: 953-959, 1999
20. Brechignac S, Hellström-Lindberg E, Bowen DT, et al. Quality of life and economic impact of red blood cell (RBC) transfusions on patients with myelodysplastic syndromes (MDS). Blood 104: 16, 2004
21. O'Brien, JA, Duran PA, Caro J. Managing myelodysplastic syndromes in the elderly with supportive therapy: case cost of transfusion therapy when inpatient care is utilized. Blood 104: #5321, 2004
22. Rizzo JD, Lichtin AE, Steven H, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol Oct 1: 4083-4107, 2002
23. Cella D, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 14: 511-519, 2003
24. Stiegler G, Sperr W, Lorber C, et al. Red cell antibodies in frequently transfused patients with myelodysplastic syndrome. Ann Hematol 80: 330-333, 2001
25. Jensen PD, Jensen FT, Christensen T, et al. Evaluation of transfusional iron overload before and during iron chelation by magnetic resonance imaging of the liver and determination of serum ferritin in adult non-thalassaemic patients. Br J Haematol 89: 880-889, 1995
26. Gandon Y, Olivie D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 363: 357-362, 2004
27. Bowen D, Culligan D, Jowitt S, et al. UK MDS Guidelines Group. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 120: 187-200, 2003
28. Borgna-Pignatti C, Franchini M, Gandini G, de Gironcoli M, et al. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. Haematologica 83: 788-790, 1998
29. Franchini M, Gandini G, de Gironcoli M, et al. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. Blood 95: 2776-2779, 2000
30. Franchini M, Gandini G, Veneri D, et al. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload: an update. Blood 103: 747-748, 2004
31. Bartlett AN, Hoffbrand AV, Kontoghiorghes GJ. Long-term trial with the oral iron chelator 1, 2-dimethyl-3 hydroxypyrid-4-one (L1). II. Clinical observations. Br J Haematol 76: 301-304, 1990
32. Kersten MJ, Lange R, Smeets ME, et al. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. Ann Hematol 73: 247-252, 1996
33. Italian cooperative study group for rHuEpo in myelodysplastic syndromes. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 103: 1070-1074, 1998
34. Hellström-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 89: 67-71, 1995
35. Mantovani L, Lentini G, Hentschel B, et al. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br J Haematol 109: 367-375, 2000
36. Terpos E, Mougiou A, Kouraklis A, et al. For The Greek MDS Study Group. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol 118: 174-180, 2002
37. Stasi R, Brunetti M, Terzoli E, et al. Once-weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosing. Ann Oncol 15: 1684-1690, 2004
38. Negrin RS, Stein R, Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 87: 4076-4081, 1996
39. Hellström-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 99: 344-351, 1997
40. Hellström-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92: 68-75, 1998
41. Thompson JA, Gilliland DG, Prchal JT, et al. Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group. Blood 95: 1175-1179, 2000
42. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, et al. Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 120: 1037-1046, 2003
43. Casadevall N, Durieux P, Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 104: 321-327, 2004
44. Miller KB, Kim HT, Greenberg P, et al. Phase III Prospective Randomized Trial of EPO with or without G-CSF Versus Supportive Therapy Alone in the Treatment of Myelodysplastic Syndromes (MDS): Results of the ECOG-CLSG Trial (E1996) Blood 104: 70, 2004
45. Clavio M, Nobili F, Balleari E, et al. Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary EPOrt. Eur J Haematol 72: 113-120, 2004
46. Howe RB, Porwit-MacDonald A, Wanat R, et al. The WHO classification of MDS does make a difference. Blood 103: 3265-3270, 2004
47. Hesketh PJ, Arena F, Patel D, et al. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer 100: 859-868, 2004
48. Musto P, Lanza F, Balleari E, et al. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 128: 204-209, 2005
49. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96: 3671-3674, 2000
50. Mannone L, Gardin C, Quarre MC, et al. High Response Rate to Darbopoetin Alfa in "Low Risk" MDS: Results of a Phase II Study. Blood 104: 69, 2004
51. Ljung T, Back R, Hellström-Lindberg E. Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors. Haematologica 89: 1446-1453, 2004
52. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 351: 1403-1408, 2004
53. Voulgari PV, Hatzimichael EC, Tsiara S, et al. Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes. Eur J Haematol 66: 31-36, 2001
54. Quint L, Casadevall N, Giraudier S. Pure red cell aplasia in patients with refractory anaemia treated with two different recombinant erythropoietins. Br J Haematol 124: 842, 2004
55. Saunthararajah Y, Nakamura R, Wesley R, et al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 102: 3025-3027, 2003
56. Wattel E, Cambier N, Caulier MT, et al. Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases. Br J Haematol 87: 205-208, 1994
57. Chan G, Di Venuti G, Miller K. Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome. Am J Hematol 71: 166-171, 2002
58. Kizaki M, Miyakawa Y, Ikeda Y. Long-term administration of pegylated recombinant human megakaryocyte growth and development factor dramatically improved cytopenias in a patient with myelodysplastic syndrome. Br J Haematol 122: 764-767, 2003
59. Kurzrock R, Cortes J, Thomas DA, et al. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol 19: 4165-4172, 2001
60. Tsimberidou AM, Giles FJ, Khouri I, et al. Low-dose interleukin-11 in patients with bone marrow failure: update of the M.D. Anderson Cancer Center experience. Ann Oncol 16: 139-145, 2005
61. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34: 730-751, 2002
62. Ganser A, Hoelzer D. Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. Semin Hematol 33: 186-195, 1996
63. Negrin RS, Haeuber DH, Nagler A, et al. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 76: 36-43, 1990
64. Rose C, Wattel E, Bastion Y, et al. Treatment with very low-dose GM-CSF in myelodysplastic syndromes with neutropenia. A EPOrt on 28 cases. Leukemia 8: 1458-1462, 1994
65. Kaczmarski RS, Pozniak A, Lakhani A, et al. A pilot study of low-dose recombinant human granulocyte-macrophage colony-stimulating factor in chronic neutropenia. Br J Haematol 84: 338-340, 1993